John R. Graybill - Concepedia

Author

John R. Graybill

The University of Texas Health Science Center at San Antonio

Also Known As

J R Graybill, J. R. Graybill, J. RICHARD GRAYBILL, J. Richard Graybill, J.R Graybill, J.R. Graybill, J. Richard Graybill, JOHN R. GRAYBILL, JOHN Richard Graybill, John Graybill

316

Publications

19.7K

Citations

H-Index

147

Concepts

All Affiliations

The University of Texas Health Science Center at San Antonio Murphy Oil Corporation (United States)Audie L. Murphy Memorial VA Hospital South Texas Veterans Health Care System United States Department of Veterans Affairs

About

John R. Graybill is an author at The University of Texas Health Science Center at San Antonio specializing in medicine, clinical microbiology, and antimicrobial resistance.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	48	113	9.7K
2	Health Sciences	28	44	2.7K
3	Engineering	4	4	241
4	Humanities	1	1	17
5	Public Health	1	1	73

John R. Graybill

191

Publications

17.3K

Citations

H-Index

Page 1

	Year	Citations
Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America John R. Perfect, William E. Dismukes, Françoise Dromer, Clinical Infectious Diseases Cryptococcal DiseasePathogenesisClinical EpidemiologyImmunologyHealthcare-associated Infection	2010	2.6K
Treatment of Cryptococcal Meningitis Associated with the Acquired Immunodeficiency Syndrome Charles M. van der Horst, Michael S. Saag, Gretchen A. Cloud, New England Journal of Medicine	1997	809
Invasive Aspergillosis Disease Spectrum, Treatment Practices, and Outcomes Thomas F. Patterson, William R. Kirkpatrick, Mary H. White, Medicine	2000	783
Diagnosis and Management of Increased Intracranial Pressure in Patients with AIDS and Cryptococcal Meningitis John R. Graybill, Jack D. Sobel, Michael S. Saag, Clinical Infectious Diseases Clinical Infectious DiseaseNeurovirologyCerebrospinal FluidImmunologyCsf Pressure	2000	483
NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis David W. Denning, Jeanette Y. Lee, J.S. Hostetler, The American Journal of Medicine	1994	451
In Vitro Activities of Posaconazole, Itraconazole, Voriconazole, Amphotericin B, and Fluconazole against 37 Clinical Isolates of Zygomycetes Qiu N. Sun, Annette W. Fothergill, Dora I. McCarthy, Antimicrobial Agents and Chemotherapy	2002	364
A Controlled Trial of Fluconazole or Amphotericin B to Prevent Relapse of Cryptococcal Meningitis in Patients with the Acquired Immunodeficiency Syndrome William G. Powderly, Michael S. Saag, Gretchen A. Cloud, New England Journal of Medicine	1992	352
Posaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other Conditions Issam Raad, Ray Hachem, Raoul Herbrecht, Clinical Infectious Diseases	2006	299
Pharmacokinetics of itraconazole following oral administration to normal volunteers T C Hardin, John R. Graybill, Richard J. Fetchick, Antimicrobial Agents and Chemotherapy Antifungal AgentPharmacological StudyMedicineAntifungal AgentsHealthy Male Volunteers	1988	296
In Vitro Activity of Caspofungin against <i>Candida albicans</i> Biofilms Stefano P. Bachmann, Kacy VandeWalle, Gordon Ramage, Antimicrobial Agents and Chemotherapy BiofilmsAntifungal AgentBiofilm FormationAntibioticsHealth Sciences	2002	288

Page 1